Radiopharm Theranostics Limited
RDPTF
$0.0113
$0.01051,312.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.11M | 660.60K | 197.00K | 98.40K | 0.00 |
| Total Other Revenue | -887.50K | 93.90K | 1.07M | 2.52M | 3.97M |
| Total Revenue | 223.80K | 754.40K | 1.27M | 2.61M | 3.97M |
| Cost of Revenue | 14.33M | 14.30M | 14.15M | 15.70M | 17.35M |
| Gross Profit | -14.11M | -13.54M | -12.88M | -13.09M | -13.38M |
| SG&A Expenses | 9.68M | 10.01M | 10.28M | 10.57M | 10.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.02M | 24.31M | 24.43M | 26.28M | 28.28M |
| Operating Income | -23.79M | -23.55M | -23.16M | -23.66M | -24.31M |
| Income Before Tax | -28.14M | -29.83M | -31.38M | -31.13M | -31.06M |
| Income Tax Expenses | 109.60K | 86.90K | 63.30K | 40.80K | 18.40K |
| Earnings from Continuing Operations | -28.25 | -29.92 | -31.44 | -31.17 | -31.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 606.40K | 661.40K | 709.70K | 709.70K | 709.70K |
| Net Income | -27.64M | -29.25M | -30.73M | -30.46M | -30.37M |
| EBIT | -23.79M | -23.55M | -23.16M | -23.66M | -24.31M |
| EBITDA | -21.77M | -21.51M | -21.11M | -21.57M | -22.17M |
| EPS Basic | -0.04 | -0.06 | -0.08 | -0.09 | -0.09 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.03 | -0.04 | -0.04 |
| EPS Diluted | -0.04 | -0.06 | -0.08 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.03 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 4.53B | 3.02B | 1.52B | 1.42B | 1.33B |
| Average Diluted Shares Outstanding | 4.53B | 3.02B | 1.52B | 1.42B | 1.33B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
